BIOMEVA and Boehringer Ingelheim strengthen their biomanufacturing services in a production alliance
Advertisement
BIOMEVA GmbH and Boehringer Ingelheim announced that both companies have entered into a production alliance agreement. With this collaboration BIOMEVA GmbH may have non-exclusive access to Boehringer Ingelheim's comprehensive manufacturing technology platform including formulation development for microbial derived products.
The collaboration with Boehringer Ingelheim complements BIOMEVA GmbH´s current manufacturing capacities with large scale manufacturing capabilities allowing speed and flexibility, and securing high value for the customers.
Already one E.coli project regarding an antibody fragment has been transferred smoothly from Boehringer Ingelheim Austria GmbH to BIOMEVA GmbH. The process has been implemented successfully in a very short time and first GMP runs have been performed already five weeks after the first technology transfer meeting. Seven weeks later GMP material has been released for clinical trials.